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Abstract Purpose:The distribution and significance of caveolin1 (CAV1) expression in different breast cell
types and role in breast carcinogenesis remain poorly understood. Both tumor-suppressive and
oncogenic roles have been proposed for this protein.The aims of this study were to characterize
the distribution of CAV1 in normal breast, benign breast lesions, breast cancer precursors,
and metaplastic breast carcinomas; to assess the prognostic significance of CAV1expression in
invasive breast carcinomas; and to define whether CAV1 gene amplification is the underlying
genetic mechanism driving CAV1overexpression in breast carcinomas.
Experimental Design: CAV1 distribution in frozen and paraffin-embedded whole tissue
sections of normal breast was evaluated using immunohistochemistry, immunofluorescence,
and immunoelectron microscopy. CAV1expression was immunohistochemically analyzed in
benign lesions, breast cancer precursors, and metaplastic breast carcinomas and in a cohort of
245 invasive breast carcinomas from patients treated with surgery followed by anthracycline-
based chemotherapy. In 25 cases, CAV1 gene amplification was assessed by chromogenic
in situ hybridization.
Results: In normal breast, CAV1was expressed in myoepithelial cells, endothelial cells, and a
subset of fibroblasts. Luminal epithelial cells showed negligible staining. CAV1was expressed in
90% of 39 metaplastic breast carcinomas and in 9.4% of 245 invasive breast cancers. In the later
cohort, CAV1expression was significantly associated with ‘basal-like’ immunophenotype and
with shorter disease-free and overall survival on univariate analysis. CAV1 gene amplification
was found in13% of cases with strong CAV1expression.
Conclusions:The concurrentCAV1amplification andoverexpression call into question its tumor-
suppressive effects in basal-like breast carcinomas.
The Caveolin 1 (CAV1) gene maps to 7q31.1 and encodes a
21- to 24-kDa integral membrane protein (1, 2). This protein
is the main component of caveolar membranes, which are
special invaginated microdomains of the plasma membrane
found in the majority of mammalian cells (1). CAV1 is
expressed in several types of human cells, including
adipocytes, endothelial cells, fibroblasts, some types of
epithelial cells, and myoepithelial cells (MEC). Owing to its
subcellular localization and ubiquitous distribution, CAV1
has been reported to play a major role in lipid transport,
membrane trafficking, gene regulation, and signal transduc-
tion (1, 2).
Conflicting results on the role of CAV1 in human cancers
have been reported (1–16). Based on the high frequency of
deletions of 7q31 (a fragile site known as FRA7G) in human
cancers (17–19), the arguable presence of CAV1 gene
promoter methylation (3, 4) and inactivating gene mutations
(3, 5), and the apparent reduction of CAV1 expression in breast
carcinomas (3, 9), it has been suggested that CAV1 is a tumor
suppressor gene (1, 2, 20). However, CAV1-null mice are no
more prone to mammary tumor development than are the
wild-type animals (20, 21). Furthermore, there is only indirect
evidence to suggest that CAV1 abrogation induces premalig-
nant alterations in mammary epithelia (22), and a proposed
inactivating mutation at codon 132 (P132L) could not be
independently validated by two groups (3, 19) and was
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reported to be restricted to estrogen receptor (ER)–positive
(luminal) breast carcinomas in a study done with DNA
extracted from formalin-fixed, paraffin-embedded tissue sec-
tions where multiple concurrent CAV1 gene mutations were
found in the same cases (23). In addition, studies showing
CAV1 down-regulation in breast cancer cell lines used unsorted
human mammary epithelial cells as reference (4) and there are
several lines of evidence to suggest that human mammary
epithelial cells, such as those used by Engelman et al. (4), show
a myoepithelial phenotype (6, 15, 24). Hence, the comparison
carried out in that study would identify genes preferentially
expressed by MECs. In fact, at least two other putative tumor
suppressor genes identified by a similar approach, maspin and
14-3-3j, have both been proven to show a preferential
myoepithelial distribution and are unlikely to be bona fide
tumor suppressor genes (16, 25–27). By contrast, there are
several lines of evidence to suggest that CAV1 may have
oncogenic properties in non–small cell lung (28), prostate
(13, 29), bladder (30), esophageal (31), thyroid (32),
pancreatic (33), and breast cancer (10, 12, 13, 16). Interest-
ingly, amplification of FRA7G site in cancer cell lines (19) and
gains of genomic material on 7q are frequently found in high-
grade breast cancer (34).
The distribution of CAV1 in normal breast, benign breast
lesions, and breast cancer precursors is controversial (3, 6,
9–11, 13, 15, 16). In a previous study comparing the
expression profiles of normal luminal epithelial and MECs of
the breast, we showed that CAV1 is one of the genes
preferentially expressed in normal MECs (6) and this has
been confirmed with in situ studies at the protein level (10,
11, 15, 16). Pinilla et al. (10) have shown recently that CAV1
is expressed in f4% of all invasive breast carcinomas, being
particularly prevalent in tumors with basal-like/myoepithelial
differentiation (10). On the other hand, Park et al. (9)
described CAV1 membrane and cytoplasmic expression in
normal luminal epithelial cells and in 57% of invasive breast
cancers (9). In this report (9), CAV1 expression was inversely
correlated with human epidermal growth factor receptor
(EGFR) 2 (HER2) or EGFR overexpression; however, the
antibody and immunohistochemical methods used were not
validated (9).
Given the controversy about the distribution of CAV1 in
breast cell types and its significance in breast carcinogenesis, we
set out to characterize the distribution of CAV1 in normal
breast samples using a combination of immunohistochemistry,
immunofluorescence, and immunoelectron microscopy. We
observed that CAV1 is preferentially expressed in MECs
compared with luminal epithelial cells. We then analyzed its
distribution in a large series of benign breast lesions, breast
cancer precursors, metaplastic breast carcinomas (tumors with
known basal/myoepithelial differentiation; refs. 35, 36), and
invasive breast carcinomas of different histologic types, grades,
and immunophenotypic profiles to determine whether CAV1
was of any diagnostic usefulness as a myoepithelial marker or
in the identification of tumors with basal-like phenotype. We
also investigated whether CAV1 gene copy number gains could
be one of the underlying genetic mechanisms driving CAV1
overexpression in breast cancers. Finally, we analyzed the
prognostic effect of CAV1 expression on the survival of 245




Samples of normal breast tissue as well as benign and malignant
breast lesions were retrieved from the archives of Royal Marsden
Hospital (London, United Kingdom), with appropriate Local Ethical
Committee approval. All cases were reviewed by experienced pathol-
ogists (J.S.R-F., F.M., and F.C.S.) and graded according to a modified
version of the Scarff-Bloom-Richardson system (37).
Normal breast, benign breast lesions, and breast cancer
precursors
Representative tissue sections of a series of benign and preinvasive
breast lesions comprised 10 normal breast tissue samples obtained
from mammoplasties, 7 apocrine changes (1 apocrine hyperplasia and
6 apocrine metaplasia), 17 fibroadenomas, 8 benign phyllodes tumors,
11 papillomas, 7 sclerosing adenosis, 8 radial scars, 9 hyperplasias of
usual type, 7 columnar cell lesions/flat atypia, and 5 pseudoangiom-
atous stromal hyperplasias.
Preinvasive lesions and invasive breast carcinomas
Malignant and premalignant lesions included 2 malignant phyllodes
tumors, 15 ductal carcinomas in situ (DCIS), and a series of 245 invasive
breast carcinomas (186 invasive ductal carcinomas, 27 invasive lobular
carcinomas, 24 invasive mixed carcinomas, and 8 invasive breast
carcinomas of other special types). All of the 245 patients with invasive
breast cancer were treated with therapeutic surgery (69 mastectomy and
155 wide local excision) and adjuvant anthracycline-based chemother-
apy, and those with ER-positive tumors also received endocrine therapy.
Follow-up was available for 245 patients, ranging from 0.5 to 135.3
months (median, 67 months; mean, 67 months). CAV1 expression was
correlated with various clinicopathologic variables, including tumor
size, tumor grade, presence of vascular invasion, presence of lymph node
metastasis, and disease-free survival (DFS) and overall survival (OS).
CAV1 expression was also correlated with that of the following
immunohistochemical markers: ER, progesterone receptor (PgR),
HER2, EGFR, cytokeratin 14, cytokeratins 5/6, cytokeratin 17, cyclin
D1 expression, and CCND1 gene amplification. All cases were classified
into luminal, HER2, basal-like, and undetermined groups according to
the immunohistochemical panel as described by Nielsen et al. (38).
Metaplastic breast carcinomas
To define the frequency of CAV1 expression in breast carcinomas
with myoepithelial phenotype, 39 cases of metaplastic breast carcino-
mas, malignant tumors with known basal/myoepithelial differentiation
(35, 36), were retrieved from the pathology files of the authors’
institutions. In all participating institutions, Local Ethics Committee
approval was obtained. Contributing authors reviewed all cases of
metaplastic breast carcinoma and did further immunohistochemical
analysis to corroborate the diagnosis. Cases were centrally reviewed by
three of the authors (J.S.R-F., F.M., and F.C.S.) on a multiheaded
microscope and classified into four categories according to the
previously described and widely accepted criteria (35, 39).
Immunofluorescence on frozen sections of normal breast
To accurately define the distribution of CAV1 in normal breast
samples, 10-Am frozen sections of normal human breast [cut onto
polylysine-coated slides (VWR, Poole, United Kingdom) and stored at
70jC] were used. When the required slides were thawed, the sections
were marked using a slide marker pen and fixed in 4% paraformalde-
hyde in PBS for 20 min at room temperature. Sections were rinsed twice
in PBS and then once in PBS plus 1% BSA plus 2% FCS (IFF). Primary
antibodies used were the following: cytokeratins 8/18 (1:100;
Novocastra), a-smooth muscle actin (1:5,000; Sigma, St. Louis, MO),
caveolin (Santa Cruz Biotechnology, Santa Cruz, CA and Transduction
Laboratories, Lexington, KY), and p63 (4A4; 1:200; Santa Cruz
Biotechnology). Antibodies were diluted in IFF and incubated for
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40 min in a moist chamber followed by 3  5–min washes in PBS and
then 40 min in conjugates diluted 1:1,000 in IFF. The following
conjugates were used in various combinations: anti-mouse IgG1–Alexa
488, anti-mouse IgG2a–Alexa 555, anti-rabbit IgG1–Alexa 488, and
anti-rabbit IgG1–Alexa 555 (Molecular Probes, Invitrogen, Paisley,
United Kingdom). Nuclei were counterstained by 3  5–min washes in
100 nmol/L Topro-3 iodide, which is a 1:10,000 dilution of stock
solution (Molecular Probes). Sections were mounted in Vectashield
(Vector Laboratories, Burlingame, CA) and sealed with nail varnish.
Slides were examined and photographed in a Leica Microsystems
(Wetzlar, Germany) TCS-SP2 confocal microscope.
Ultrastructural analysis
Postembedding immunogold labeling of normal breast samples. Small
pieces of normal human breast were fixed for 1 h at room temperature
in 2% paraformaldehyde + 0.05% glutaraldehyde in PBS. The pieces
were then embedded in Lowicryl HM20 resin using the progressive
lowering of temperature technique as described previously (40). For
immunogold labeling, 80-nm sections were cut onto naked nickel grids.
Antibody incubation was overnight at 4jC in a moist chamber followed
by a 90-min incubation with 5- or 10-nm gold conjugates (Aurion,
Wageningen, the Netherlands). For low-power work, sections were
silver enhanced with IntenSE (GE Healthcare, Amersham, United
Kingdom). In double labeling experiments, no enhancement was used.
Sections were counterstained with uranyl acetate and lead citrate and
examined in an FEI (Hillsboro, OR) CM100 Biotwin electron
microscope at 80 Kv accelerating voltage.
Immunohistochemistry
Owing to the heterogeneous distribution of CAV1 staining, whole
tissue sections of benign breast lesions, breast cancer precursors, and
invasive breast carcinomas were subjected to immunohistochemical
analysis. Representative formalin-fixed, paraffin-embedded tissue sec-
tions were subjected to immunohistochemical analysis as described
previously (41), with the mouse monoclonal antibody 2297 (Trans-
duction Laboratories; ref. 10) at 1:150 dilution following heat-induced
antigen retrieval [18 min, microwave oven, DAKO antigen retrieval
solution (pH 6.0)]. Detection was achieved with the Vector avidin-
biotin complex (ABC) system (Vector Laboratories). Positive controls
(capillaries of normal breast and skin sections) and negative (omission
of the primary antibody- and IgG-matched serum) controls were done
for each immunohistochemical run. Furthermore, all sections had
internal positive controls for CAV1 (nonneoplastic endothelial cells).
The distribution of CAV1 in tissue sections was assessed by two of the
authors (K.S. and J.S.R-F.) on a multiheaded microscope. A consensus
score was assigned for each case. The distribution and intensity of CAV1
staining were evaluated semiquantitatively: distribution: 0, <1% of cells
stained; 1, 1% to <10%; 2, z10% to <25%; 3, z25% to <50%; and 4,
z50%. The staining intensity in neoplastic cells was determined by a
comparison with the expression of CAV1 in normal endothelial cells: 0,
no staining in neoplastic cells; 1, weak staining; 2, moderate staining
(slightly weaker than that seen in endothelial cells); and 3, strong
staining (of similar intensity to that seen in endothelial cells). Invasive
breast carcinomas with final scores (sum of distribution and intensity
scores) z4 were considered positive. Only membranous with or
without cytoplasmic staining was considered specific.
Data on the expression of ER, PgR, HER2, EGFR, cytokeratin 14,
cytokeratins 5/6, and cytokeratin 17 in the invasive tumors and meta-
plastic breast carcinomas were described in detail elsewhere (35, 41).
Chromogenic in situ hybridization
To evaluate whether CAV1 gene amplification might be the
underlying genetic mechanism for CAV1 expression in metaplastic
and basal-like invasive ductal breast carcinomas, we analyzed 25 cases,
15 with strong CAV1 expression and 10 devoid of CAV1 staining, by
means of chromogenic in situ hybridization using an in-house
generated probe made up of two contiguous, fluorescent in situ
hybridization mapped, bacterial artificial chromosome clones (RP11-
691L23 and RP11-730H09), which map to 7q31.1 (115.6-115.8 Mb)
and do not span the MET gene (115.9-116.0 Mb), according to
Ensembl Genome Browser.7 The in-house probe was generated, biotin
labeled, and used in hybridizations according to a protocol described
by Lambros et al. (42). Hybridizations were done as described
previously. Chromogenic in situ hybridization experiments were
analyzed by two of the authors (K.S. and J.S.R-F.) on a multiheaded
microscope. Only unequivocal signals were counted at  400
(chromogenic in situ hybridization) in 60 morphologically unequivocal
neoplastic cells. Amplification was defined as more than five signals per
nucleus in >50% of cancer cells or when large gene copy clusters were
seen (42, 43). All chromogenic in situ hybridizations were evaluated
with observers blinded to the immunohistochemical results.
Statistical analysis
The StatView 5.0 software package (SAS Institute, Inc., Cary, NC)
was used for all calculations. Correlations between categorical
variables were done using the m2 test and Fisher’s exact test. Correla-
tions between continuous and categorical variables were done with
ANOVA. DFS and OS were expressed as the number of months from
diagnosis to the occurrence of an event (local recurrence/metastasis
and disease-related death, respectively). Cumulative survival proba-
bilities were calculated using the Kaplan-Meier method. Differences
between survival rates were tested with the log-rank test. All tests were
two tailed, with a confidence interval of 95%.
Multivariate analysis was done using the Cox multiple hazard model.
A P value of 0.05 in the univariate survival analysis was adapted as the
limit for inclusion in the multivariate model. Cases with missing values
were excluded in the multivariate analysis model.
Results
Normal breast tissue. CAV1 was expressed consistently in
MECs arranged as a continuous layer around ducts and lobular
units, whereas luminal epithelial cells were devoid of any
staining (Fig. 1). Because antigen retrieval was required for
immunohistochemical analysis of CAV1 on formalin-fixed
paraffin-embedded tissue sections, we analyzed the distribution
of this protein on frozen tissue sections using double and triple
immunolabeling fluorescent microscopy and immunoelectron
microscopy (44). The distribution of CAV1 in normal MECs
proved to be similar to that of traditional myoepithelial
markers, such as p63 and a-smooth muscle actin (Fig. 1).
Interestingly, ductal MECs were consistently strongly decorated
by CAV1, whereas MECs of the lobules occasionally showed
moderate-to-strong staining. Luminal epithelial cells showed
negligible expression of CAV1 in frozen tissue sections and
lacked any CAV1 in formalin-fixed paraffin-embedded sections.
At the ultrastructure level, abundant CAV1-positive caveolae
were found in MECs, whereas CAV1-positive caveolae were
exceedingly rare in luminal epithelial cells (Fig. 1).
The stromal compartments of the breast showed a differential
distribution of CAV1: intralobular fibroblasts (i.e., fibroblasts
of the modified stroma) showed strong membranous staining
for CAV1, whereas interlobular fibroblasts and periductal
fibroblasts were either negative or showed weak-to-moderate
staining. Adipocytes and endothelial cells showed consistent,
strong staining (Fig. 1), whereas perineurial cells displayed
moderate intensity staining. Given that endothelial cells were
consistently positive for CAV1, immunohistochemical staining
7 http://www.ensembl.org.
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Fig. 1. CAV1expression in normal breast. CAV1was strongly expressed in capillaries, adipocytes, myofibroblasts, and MECs (red ; A, D, E, and G). In normal breast acini
(B, E , and H) and ducts (C, F, and I), CAV1was preferentially expressed in MECs. Expression of CAV1was consistently seen in p63-positive MECs (green ; D-F) and not
in cytokeratin 8/18^ positive luminal epithelial cells (green ; A-C). Note the CAV1and a-smooth muscle actin (green ; G-I) coexpression in MECs and scattered fibroblasts
(coexpression; yellow). Expression of CAV1in a formalin-fixed paraffin-embedded section of normal breast (J). Note its similar distribution when compared with that seen
in frozen sections. In both frozen and formalin-fixed tissue sections, luminal epithelial cells displayed negligible staining with CAV1antibodies. Double immunoelectron
microscopy for a-smooth muscle actin (10-nm gold particles) and CAV1 (5-nm gold particles) in a MEC (K). Note the presence of caveolae with positive staining for CAV1
(arrow). Original magnifications,40 (A, D, and G), 200 (B, C, E, F, H, and I), and100 (J). Bar, 200 nm (K).
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for CAV1 in these structures served as reference staining and
internal control for the experiments.
Benign breast lesions/fibrocystic changes. Apocrinemetaplasia
andhyperplasia (Table 1) displayedCAV1 expression in the form
of a continuous layer of CAV1-positive MECs surrounding
CAV1-negative apocrine cells; however, the intensity varied from
moderate to high. This subtle decrease of CAV1 staining was also
noticed in dilated ducts of specimens with fibrocystic change.
Intraductal papilloma. CAV1 was consistently positive in the
MECs and in endothelial cells of capillaries found in the fibro-
vascular cores (Fig. 2A and B). Scattered luminal cells showed
weak-to-moderate positivity in five cases. Fibroblasts of the fibro-
vascular cores were usually negative, unlike those of sclerotic
zones, which expressed moderate-to-strong levels of CAV1.
Radial scar. CAV1 was positive in the outer MECs of ductal
structures in all cases, whereas luminal epithelial cells
consistently lacked this marker. Of note, ducts entrapped in
the central elastotic areas showed a moderate-to-strong staining
in MECs; however, adjacent fibroblasts were also positive,
making the interpretation difficult at times (Fig. 2C and D).
Capillaries and endothelial cells of medium-sized and large
vessels showed consistent CAV1 expression.
CAV1 expression in breast cancer precursors. Data on CAV1
expression in breast cancer precursors are summarized in Table
1. All hyperplasias of usual type exhibited a continuous or near-
continuous layer of CAV1-stained MECs; in these lesions, the
solid areas of proliferating hyperplastic cells were weakly-to-
moderately positive for CAV1 (Fig. 2E and F).
In columnar cell lesions and DCIS, CAV1 was consistently
expressed in a continuous/near-continuous layer of MECs
(Fig. 2G and H). However, the staining intensity of CAV1 was
never as strong and consistent as that seen with p63 and SMM-
HC (data not shown). Furthermore, a variable number of
neoplastic cells also showed weak-to-moderate positivity in two
columnar cell lesions and one DCIS. In five samples of DCIS,
CAV1 was consistently positive in stromal cells (myofibro-
blasts) arranged in an onionskin pattern surrounding the
affected ducts.
Metaplastic breast carcinomas consistently overexpress CAV1.
All metaplastic breast carcinomas included in this study
showed the typical immunohistochemical profile of basal-like
breast carcinomas (i.e., ER and HER2 negative and positive for
either cytokeratins 5/6 and/or EGFR; Fig. 3; ref. 38). Thirty-five
(89.7%) of 39 samples were considered positive for CAV1
(Table 1).
Correlation between CAV1 and clinicopathologic variables and
immunohistochemical markers. CAV1 expression was found in
9.4% of 245 cases (Fig. 3) of invasive breast carcinomas. Of
the positive cases, seven (30.4%) were of score 4, nine
(39.1%) were of score 5, five (21.7%) were of score 6, and
two (8.7%) were of score 7. CAV1 expression showed a strong
correlation with histologic grade and lack of lymph node
metastasis. When compared with the expression of other
immunohistochemical markers, an inverse correlation be-
tween CAV1 and ER, PgR, HER2, and cyclin D1 expression
was observed. In addition, CAV1 expression showed a strong
Table 1. CAV1 distribution in benign breast lesions, breast cancer precursors, and metaplastic breast
carcinomas
n Myoepithelial compartment* Luminal compartment*
CAV1 scores, % cases CAV1 scores, % cases
0 2 3 4 5 6 7 0 2 3 4 5 6 7
Benign lesions
Apocrine change 7 0 0 0 42.9 28.6 14.3 14.3 100 0 0 0 0 0 0
Papilloma 11 0 0 0 9.1 9.1 36.4 45.5 54.5 0 36.4 9.1 0 0 0
Radial scar 8 0 0 0 12.5 25.0 37.5 25.0 100 0 0 0 0 0 0
Sclerosing adenosis 7 0 0 0 0 14.3 28.6 57.1 100 0 0 0 0 0 0
Fibroadenoma 17 0 11.8 5.9 23.5 35.3 17.6 5.9 70.6 11.8 5.9 11.8 0 0 0
Benign phyllodes tumor 8 0 0 12.5 12.5 37.5 37.5 0 50 0 37.5 12.5 0 0 0
Precursors
HUT 9 0 0 0 0 44.4 44.4 11.1 0 33.3 22.2 22.2 22.2 0 0
CCL 7 0 0 0 0 42.9 42.9 14.2 71.4 0 14.3 0 14.3 0 0
DCIS 15 0 0 0 26.7 33.3 20 40 86.6 0 0 0 6.7 0 6.7
n Neoplastic cells*
CAV1 scores, % cases
0 2 3 4 5 6 7
Metaplastic carcinomas 39 0 0 10.2 20.5 10.3 30.8 28.2
Spindle cell carcinomas 19 0 0 10.5 5.3 5.3 36.8 42.1
Carcinoma with
squamous metaplasia
7 0 0 14.3 42.9 14.3 28.6 0.0
Matrix-producing carcinoma 10 0 0 10.0 30.0 20.0 30.0 10.0
Carcinoma with
heterologous elements
3 0 0 0.0 33.3 0.0 0.0 66.7
Abbreviations: HUT, hyperplasia of usual type; CCL, columnar cell lesion.
*Semiquantitative scoring system: sum of the scores for distribution (distribution: 0, <1% of cells stained; 1, 1% to <10%; 2, z10% to <25%;
3, z25% to <50%; and 4, z50%) and intensity [0, no staining in neoplastic cells; 1, weak staining; 2, moderate staining (slightly weaker than
that seen in endothelial cells); and 3, strong staining (of similar intensity to that seen in endothelial cells)].
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statistical association with the expression of EGFR, cytokeratins
5/6, cytokeratin 14, cytokeratin 17, and ‘basal markers’; high
MIB-1 proliferation index; and p53 immunoexpression. When
CAV1 was correlated with the immunohistochemical groups
defined by Nielsen et al. (38), all but one of CAV1-positive cases
were classified as basal-like carcinomas. These results are
displayed in Table 2.
In this cohort of patients, univariate analysis revealed grade,
presence of lymph node metastasis, ER, PgR, and cytokeratin
17; and proliferation index assessed by MIB-1 were statistically
significant predictors of DFS, whereas presence of lymph node
metastasis, ER, PgR, cytokeratins 5/6, cytokeratin 14, and
cytokeratin 17; proliferation index assessed by MIB-1; p53
immunoexpression; and cyclin D1 expression were significantly
Fig. 2. CAV1expression in papilloma
(A and B), radial scar (C and D),
hyperplasia of usual type (E and F), and
ductal carcinoma in situ (G and H).
Low-power magnification of a papilloma
(A, H&E). Note the specific staining in the
continuous layer of MECs and endothelial
cells of vessels in the papillary cores
(arrowhead) and lack of staining in luminal
cells [B, ABC/3,3¶-diaminobenzidine
(DAB)]. Low-power magnification of the
central area of a radial scar (C, H&E). Note
the expression of CAV1in MECs, fibroblasts,
and capillaries (D, ABC/DAB). Inset, note
the presence of CAV1expression in the
MECs surrounding a duct in a sclerotic zone.
CAV1expression in hyperplasia of usual
type (E , H&E). Note the presence of CAV1-
positive MECs surrounding ductal structures
and admixed with the hyperplastic
population (F, ABC/DAB). CAV1expression
in a grade 3, comedo DCIS (G, H&E; H,
ABC/DAB). Note the expression of CAV1in
MECs, endothelial cells, and scattered
fibroblasts. Original magnifications,100
(A, B, C, D, G, and H) and 200 (E and F).
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associated with OS (Table 3). In univariate analysis, tumors
expressing CAV1 showed a significantly shorter DFS and OS
(Table 3). These associations were also significant when
considering only lymph node metastasis-positive patients and
the OS of lymph node metastasis-negative patients (data not
shown).
On multivariate analysis, only size, grade, and presence of
lymph node metastasis were independent prognostic factors for
DFS, whereas lymph node metastasis, cytokeratin 17 expression,
and p53 expression were independent prognostic factors for OS
(data not shown).
CAV1 gene amplification is the underlying genetic cause for
caveolin expression in a subset of invasive breast cancers. Given
that the locus of CAV1 is reported to be frequently gained in
basal-like breast cancer (34), we investigated whether CAV1
amplification would be the underlying genetic mechanism
Fig. 3. CAV1expression and CAV1gene
amplification in invasive carcinomas. A and
B, grade 3 ER-negative basal-like invasive
ductal carcinoma (A , H&E; B, ABC/DAB)
displaying positivity for CAV1. C and D,
matrix-producing metaplastic breast
carcinoma (C, H&E; D, ABC/DAB) with
strong and diffuse staining. E and F,
metaplastic spindle cell carcinoma (E , H&E;
F, ABC/DAB) with diffuse and strong CAV1
expression. G and H, metaplastic spindle
cell carcinoma harboring strong CAV1
expression (G, ABC/DAB) and gene
amplification (H, DAB) in the form of more
than five signals in the nuclei of neoplastic
cells. Note stromal cells with one or
two copies of CAV1 (arrows). Original
magnifications, 100 (A-F), 400 (G), and
630 (H).
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Table 2. Correlations between CAV1 expression, clinicopathologic variables, and immunohistochemical
markers in 245 invasive breast carcinomas
Variable N NA CAV1  (%) CAV1 + (%) P
Size 243 2 0.8930*
T1 115 (90.6) 12 (9.4)
T2 90 (90) 10 (10)
T3 15 (93.8) 1 (6.3)
Grade 240 5 0.0028*
1 23 (100) 0 (0)
2 68 (98.6) 1 (1.4)
3 127 (85.8) 21 (14.2)
Type 245 0 0.2370*
IDC 167 (89.8) 19 (10.2)
ILC 26 (96.3) 1 (3.7)
Mixed 23 (95.8) 1 (4.2)




 72 (87.8) 10 (12.2)
+ 148 (91.9) 13 (8.1)
Lymph node metastasis 237 8 0.0023c
 68 (81.9) 15 (18.1)
+ 146 (94.8) 8 (5.2)
ER 241 4 <0.0001c
 26 (54.2) 22 (45.8)
+ 192 (99.5) 1 (0.5)
PgR 241 4 <0.0001c
 45 (69.2) 20 (30.8)
+ 173 (98.3) 3 (1.7)
HER2 238 7 0.0302c
 179 (88.6) 23 (11.4)
+ 36 (100) 0 (0)
EGFR 245 0 <0.0001c
 215 (96.4) 8 (3.6)
+ 7 (31.8) 15 (68.2)
Ck-14 243 2 <0.0001c
 213 (96.4) 8 (3.6)
+ 7 (31.8) 15 (68.2)
Ck-5/6 235 10 <0.0001c
 203 (96.7) 7 (3.3)
+ 10 (40) 15 (60)
Ck-17 241 4 <0.0001c
 204 (95.8) 9 (4.2)
+ 14 (50) 14 (50)
Basal markers 235 10 <0.0001c
 193 (99) 2 (1)
+ 19 (47.5) 21 (52.5)
Nielsen groups 232 13 <0.0001*
Basal 9 (30) 21 (70)
Luminal 165 (99.4) 1 (0.6)
HER2 36 (100) 0 (0)
p53 226 19 0.0002c
 151 (95) 8 (5)
+ 52 (77.6) 15 (22.4)
MIB-1 (%) 227 18 <0.0001*
<10 97 (100) 0 (0)
10-30 89 (91.8) 8 (8.2)
>30 18 (54.5) 15 (45.5)
Cyclin D1 <0.0001*
Negative 224 21 15 (57.7) 11 (42.3)
Moderate 39 (83) 8 (17)
Strong 147 (97.4) 4 (2.6)
CCND1 amplification 206 39 0.3238c
No amplification 156 (88.6) 20 (11.4)
Amplification 29 (96.7) 1 (3.3)
NOTE: Nielsen groups are immunophenotypic groups defined based on the expression of ER, HER2, cytokeratins 5/6, and EGFR.
Abbreviations: Ck, cytokeratin; CCND1, cyclin D1 gene; NA, not accessible; IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma.
*m2 test.
cFisher’s exact test.
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driving the expression of CAV1. We analyzed 15 cases with
strong CAV1 expression (5 metaplastic breast carcinomas and
10 grade 3 invasive ductal carcinomas) and 10 cases without
CAV1 expression (10 invasive ductal carcinomas). Two (one
metaplastic breast carcinoma and one grade III, ER, PgR, HER2,
and basal keratin plus invasive ductal carcinoma) of 15 cases
with strong CAV1 expression (13%) showed gene amplification
(Fig. 3E and F), whereas none of the cases without CAV1
Table 3. Univariate survival analysis of 245 breast cancer patients treated with surgery followed by
anthracycline-based adjuvant chemotherapy
Variable n (%) Events DFS (mean F SD) P, log-rank test Events OS (mean F SD) P , log-rank test
Size <0.005 >0.1
T1 127 (52.3) 25 111.7 F 4.33 20 115.4 F 4.09
T2 100 (41.1) 31 99.2 F 5.41 18 114.9 F 4.35
T3 16 (6.6) 9 54.9 F 7.45 4 76.4 F 7.47
Grade <0.005 <0.1
1 23 (9.6) 1 116.8 F 3.94 1 117 F 3.64
2 69 (28.7) 12 116.4 F 4.98 8 121 F 4.93
3 148 (61.7) 50 95.9 F 4.52 33 109 F 4.00
Lymph node metastasis <0.0001 <0.0005
No 83 (35.0) 10 122.2 F 3.96 5 129 F 2.60
Yes 154 (65.0) 54 93.5 F 4.61 37 105 F 4.32
Lymphovascular invasion >0.1 >0.1
No 82 (33.7) 19 109.9 F 5.18 11 121 F 4.15
Yes 161 (66.3) 46 94.9 F 4.04 31 104 F 3.73
ER <0.05 0.0001
Negative 48 (20.1) 19 81.2 F 6.94 17 86.8 F 6.53
Positive 191 (79.9) 44 107.9 F 3.73 24 119.2 F 3.17
PgR >0.1 <0.0005
Negative 64 (26.8) 21 89.3 F 6.25 20 92.8 F 5.84
Positive 175 (73.2) 42 106.9 F 3.92 21 119.7 F 3.33
HER2 >0.1 >0.1
Negative 200 (84.7) 52 104.3 F 3.75 32 115 F 3.43
Positive 36 (15.3) 11 92.9 F 7.71 9 102 F 7.28
EGFR >0.1 <0.1
Negative 222 (91.0) 57 105 F 3.55 35 115.5 F 3.18
Positive 22 (9.0) 8 86 F 9.62 7 92.3 F 8.79
Ck-14 >0.1 <0.05
Negative 221 (90.9) 57 104.2 F 3.65 34 116.0 F 3.13
Positive 22 (9.1) 8 84.5 F 10.13 8 86.6 F 9.47
Ck-5/6 <0.1 <0.01
Negative 210 (89.4) 53 105.4 F 3.63 32 116.2 F 3.19
Positive 25 (10.6) 10 80.4 F 9.81 9 86.8 F 8.95
Ck-17 <0.05 <0.0001
Negative 213 (88.4) 51 106.5 F 3.60 28 118.5 F 3.06
Positive 28 (11.6) 12 77.2 F 9.41 12 80.3 F 8.72
Basal markers <0.05 <0.001
Negative 204 (84.0) 49 106.8 F 3.67 28 117.7 F 3.19
Positive 39 (16.0) 16 79.4 F 7.85 14 87.1 F 7.13
Nielsen groups >0.1 <0.005
Basal 30 (13.0) 12 81.3 F 8.74 11 87.2 F 8.01
Luminal 164 (71.3) 11 92.9 F 7.71 19 102.2 F 7.28
HER2 36 (15.7) 37 107.9 F 4.13 9 119.1 F 3.68
p53 <0.05 <0.001
Negative 158 (70.2) 37 107.8 F 3.99 18 120 F 3.52
Positive 67 (29.8) 23 94.9 F 6.93 20 103 F 6.06
MIB-1 (%) <0.05 <0.005
<10 96 (42.5) 18 112.2 F 5.04 11 122.4 F 3.66
10-30 97 (42.9) 29 100.8 F 5.47 16 111.4 F 5.48
>30 33 (14.6) 15 76.4 F 8.38 13 88.8 F 8.44
Cyclin D1 <0.1 <0.05
Negative/Weak 26 (11.7) 11 70.8 F 7.81 26 81.1 F 7.64
Moderate 46 (20.6) 12 86.8 F 6.04 46 106.2 F 6.29
Strong 151 (67.7) 36 107.7 F 4.08 151 118.2 F 3.51
CCND1 >0.1 >0.1
Nonamplified 211 (87.6) 56 103.6 F 3.67 37 114 F 3.25
Amplified 30 (12.4) 9 94.8 F 8.17 5 107 F 6.81
CAV1 <0.05 <0.05
Negative 221 (90.6) 55 160 F 3.48 34 116.3 F 3.08
Positive 23 (9.4) 10 71.4 F 8.17 8 82.2 F 7.91
NOTE: Nielsen groups are immunophenotypic groups.
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expression showed abnormal CAV1 gene copy numbers. In the
two cases with CAV1 amplification, normal chromosome 7
centromere copy numbers were observed and the ratios CAV1/
chromosome 7 copy numbers were >2.0 (data not shown).
Discussion
Using a combination of immunofluorescence, ultrastructural
analysis, and immunohistochemistry, we have shown that
CAV1 is preferentially expressed in MECs, fibroblasts, and
endothelial cells in normal breast tissue. Luminal epithelial
cells showed a negligible expression of CAV1 in our immuno-
fluorescence and immunoelectron microscopic analyses. At
variance with previous studies, where CAV1 was reported to be
expressed in normal luminal epithelial cells of the breast, our
results provide definite data on the lack of CAV1 expression in
normal luminal cells and consistent expression in MECs of the
breast. These results not only corroborate but also expand the
findings of our group and others (6, 10, 11, 15), who have
described consistent expression of CAV1 in MECs at the mRNA
and protein levels and lack of expression in luminal epithelial
cells of normal breast.
Strategies that have been used to determine the tumor-
suppressive functions of CAV1 in human breast cancer have
included the following: (a) knockout of CAV1 gene in cells
with a luminal phenotype (22, 23) and (b) comparisons
between breast cancer and cultured unsorted breast epithelial
cells/human mammary epithelial cells (HMECs; ref. 4). How-
ever, as the majority of breast carcinomas harbor a luminal or
HER2 immunophenotype and cultured unsorted breast epithe-
lial cells/human mammary epithelial cells (HMECs) consis-
tently harbor a basal/myoepithelial phenotype, the results of
our study call into question these means of determining tumor-
suppressive functions of CAV1.
Furthermore, our findings contradict those of Li et al. (23)
proposing a ’novel pathway leading toward mammary ‘tumor-
igenesis’, involving down-regulation of CAV1 by loss of
function or genetic ablation of CAV1 gene expression in
normal epithelial cells and thus driving tumorigenesis of
estrogen-positive breast carcinomas by increasing ER levels
(23). In fact, according to our results and those of other groups
(10, 15), using comprehensively validated immunohistochem-
ical methods, normal luminal epithelial cells of the human
breast express negligible levels of CAV1. Therefore, we do not
dispute that the pathway described Li et al. (23) may take place
in engineered mouse models; however, it is unlikely to take
place in human breast.
CAV1 showed consistent expression in MECs of radial scar,
sclerosing adenosis, columnar cell lesion, and DCIS; however,
its intensity was variable. That is not surprising given that
different levels of CAV1 expression were seen in ductal and
lobular MECs. Moreover, CAV1 was frequently expressed in
myofibroblasts surrounding ducts affected by DCIS and in
endothelial cells. Therefore, we would not advocate the use of
CAV1 as a myoepithelial marker to differentiate between
noninvasive and invasive breast lesions. On the other hand,
CAV1 seems to be a useful marker to identify tumors with
basal-like phenotype. In the present study, all metaplastic
breast carcinomas, tumors with known basal-like/myoepithe-
lial phenotype, displayed CAV1 expression, and 70% of
invasive ductal carcinomas with basal-like phenotype (Table 2)
showed positivity for this marker. These results agree with those
of previous studies that showed that CAV1 is preferentially
expressed in tumors and breast cancer cell lines with basal-like
immunophenotype as defined by cDNA microarrays or
immunohistochemistry (10, 15).
In the present study, CAV1 expression was significantly
associated with high histologic grade and lack of hormone
receptors and HER2 expression and directly correlated with p53
immunoexpression and high proliferation rates, all features of
basal-like breast carcinomas. CAV1 expression was significantly
correlated with positivity for EGFR (i.e., CAV1 was expressed in
68% of EGFR-positive breast cancers, whereas only 3.6% of
EGFR-negative breast carcinomas displayed CAV1 expression).
Initial studies suggested that EGFR would be localized to
caveolae and that CAV1 expression might modulate EGFR
signaling activity by receptor sequestration and also played a
role in controlling receptor trafficking (45, 46). However, there
are several lines of evidence to suggest that interactions between
CAV1 and EGFR are cell type and context dependent (45). On
the other hand, it has been shown recently that EGFR and
CAV1 are coexpressed in several tumor types (10, 45, 47) but
do not necessarily colocalize to the same subcellular compart-
ment (45, 48). More recent data, based on ultrastructural
analysis, show that EGFR seems to be expressed in flat lipid rafts
rather than caveolae (45, 48). There is compelling evidence to
suggest that EGFR phosphorylation negatively modulates direct
interactions between EGFR and CAV1 and that EGFR signaling
activation down-regulates CAV1 levels (47, 49). In fact, in
glioblastoma cells harboring EGFR gene amplification or
mutation, overexpression of CAV1 does not abrogate EGFR
activity when EGFR is phosphorylated (47). In addition, under
oxidative stress, CAV1 is hyperphosphorylated and transports
EGFR to a perinuclear location where it is not degraded and
remains active (46). Recently, it has been shown that EGFR-
driven Wnt pathway activation seems to be dependent on EGFR-
induced CAV1 down-regulation (49). Given the conflicting
information on the interactions between CAV1 and EGFR, the
cell type–dependence of CAV1 functions, and the role played
by the signaling pathways activated by EGFR phosphorylation
(i.e., ERK, phosphatidylinositol 3-kinase, and Wnt pathways) in
the biology of basal-like breast cancer, further studies analyzing
the mechanistic interactions between CAV1 and EGFR signaling
in basal-like breast carcinomas are warranted.
CAV1 expression was significantly associated with a shorter
OS; however, it did not prove to be an independent prognostic
factor in multivariate survival analysis. Our findings are at
variance with those of other studies where nonmicrodissected
breast cancer samples were subjected to real-time PCR analysis
of CAV1 mRNA levels (11). Given that CAV1 is consistently
expressed in myofibroblasts and endothelial cells, an accurate
measurement of CAV1 mRNA levels in neoplastic cells is not
possible without precise microdissection or by using in situ
methods. Therefore, those results (11) should be interpreted
with caution. In addition, due to the particular characteristics of
our series (i.e., patients who received adjuvant anthracyclines),
our results may not be applicable to the general population of
early breast cancer patients.
Given that CAV1 is preferentially expressed in basal-like
breast carcinomas, which are consistently of high histologic
grade (10), and that gains of 7q are reported to be frequently
found in high-grade breast carcinomas (34, 50), we sought to
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define whether CAV1 gene amplification would be the
underlying genetic mechanism driving CAV1 expression.
CAV1 amplification was seen in 13% of the strong CAV1
expressers and in none of cases without CAV1 expression,
suggesting that at least in a subgroup of basal-like breast
carcinomas, CAV1 expression is driven by gene copy number
gains. These findings agree with those of Jones et al. (34), where
tumors with basal-like phenotype as defined by cytokeratin 14
showed copy number gains of 7q in 14% of cases and no
deletions of this chromosomal arm (34). Although CAV1-
specific probes were used, we cannot rule out thatMET was also
coamplified in the two cases analyzed in this study.
The underlying mechanism of CAV1 expression in the
majority of cases remains to be elucidated. Given that CAV1 is
consistently expressed in normal MECs (6, 10, 11) and tumors
with basal and/or myoepithelial differentiation (10, 15), it is
possible that CAV1 expression in basal-like breast carcinomas
might constitute the maintenance of a myoepithelial phenotype
or might be part of a transcriptomic program of myoepithelial/
basal-like differentiation.
In summary, our findings and those of other recently
reported studies show that CAV1 is consistently expressed in
MECs and in a subgroup of breast carcinomas with basal-like
phenotype. On univariate analysis, overexpression of CAV1
was associated with high histologic grade, high proliferation
rates, and p53 immunoexpression and with shorter DFS and
OS. However, on multivariate analysis, CAV1 was not a
significant independent prognostic factor for DFS and OS. In
up to 13% of the cases with CAV1 expression, CAV1 gene
amplification was found and is likely to be the driving
mechanism of CAV1 overexpression in these cases. Taken
together, these findings call into question the tumor-suppres-
sive functions of CAV1 in breast cancer, particularly in the
subgroup of basal-like breast carcinomas. Further studies to
define the oncogenic properties of CAV1 in basal-like breast
carcinomas are warranted.
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